In order to elucidate the metabolite receptor (MR) expression landscape in IBD, we performed a differential expression analysis of intestinal biopsies from CD and UC patients, comparing their expression to healthy individuals (HI; control group). Here, NR3C2 is linked to inflammatory bowel disease.